A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase III Trial of Everolimus + Octreotide LARvs.Placebo + Octreotide LAR in Patients with Advanced Neuroendocrine Tumors (NET) (RADIANT-2): Updated Safety Results

Updated Results from the Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Trial (RADIANT-3) of Everolimus in Patients with Advanced Pancreatic Neuroendocrine Tumors (pNET)

The American Journal of Gastroenterology ◽

10.14309/00000434-201110002-00145 ◽

2011 ◽

Vol 106 ◽

pp. S59 ◽

Cited By ~ 1

Author(s):

Edward Wolin ◽

Rodney Pommier ◽

Jeremie Lincy ◽

Robert Winkler ◽

James Yao

Keyword(s):

Neuroendocrine Tumors ◽

Phase Iii ◽

Double Blind ◽

Phase Iii Trial ◽

Double Blind Placebo ◽

Everolimus in patients with advanced pancreatic neuroendocrine tumors (pNET): Updated results of a randomized, double-blind, placebo-controlled, multicenter, phase III trial (RADIANT-3).

Journal of Clinical Oncology ◽

10.1200/jco.2011.29.15_suppl.4009 ◽

2011 ◽

Vol 29 (15_suppl) ◽

pp. 4009-4009 ◽

Cited By ~ 3

Author(s):

J. R. Strosberg ◽

J. Lincy ◽

R. E. Winkler ◽

E. M. Wolin

Keyword(s):

Neuroendocrine Tumors ◽

Phase Iii ◽

Double Blind ◽

Phase Iii Trial ◽

Double Blind Placebo ◽

Everolimus (Eve) for the Treatment of Advanced Pancreatic Neuroendocrine Tumors (Pnet): Final Overall Survival (Os) Results of a Randomized, Double-Blind, Placebo (Pbo)-Controlled, Multicenter Phase III Trial (Radiant-3)

Annals of Oncology ◽

10.1093/annonc/mdu345.1 ◽

2014 ◽

Vol 25 ◽

pp. iv394 ◽

Cited By ~ 5

Author(s):

J.C. Yao ◽

M. Pavel ◽

C. Lombard-Bohas ◽

E. van Cutsem ◽

D. Lam ◽

...

Keyword(s):

Overall Survival ◽

Neuroendocrine Tumors ◽

Phase Iii ◽

Double Blind ◽

Phase Iii Trial ◽

Double Blind Placebo ◽

A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase III Trial of Everolimus in Patients with Advanced Pancreatic Neuroendocrine Tumors (pNET) (RADIANT-3): Updated Safety Results

10.1210/endo-meetings.2011.part3.or6.or25-2 ◽

2011 ◽

pp. OR25-2-OR25-2

Author(s):

Dieter Horsch ◽

Catherine Lombard-Bohas ◽

Jeremie Lincy ◽

Stephen Saletan ◽

Walter Kocha

Keyword(s):

Neuroendocrine Tumors ◽

Phase Iii ◽

Double Blind ◽

Phase Iii Trial ◽

Double Blind Placebo ◽

A randomized, double-blind, placebo (P) controlled, multicenter phase III trial to evaluate the efficacy and safety of adding bevacizumab (B) to erlotinib (E) and gemcitabine (G) in patients (pts) with metastatic pancreatic cancer

Journal of Clinical Oncology ◽

10.1200/jco.2008.26.15_suppl.4507 ◽

2008 ◽

Vol 26 (15_suppl) ◽

pp. 4507-4507 ◽

Cited By ~ 23

Author(s):

W. Vervenne ◽

J. Bennouna ◽

Y. Humblet ◽

S. Gill ◽

M. J. Moore ◽

...

Keyword(s):

Pancreatic Cancer ◽

Phase Iii ◽

Metastatic Pancreatic Cancer ◽

Efficacy And Safety ◽

Double Blind ◽

Phase Iii Trial ◽

Double Blind Placebo ◽

Lenercept (p55 tumor necrosis factor receptor fusion protein) in severe sepsis and early septic shock: A randomized, double-blind, placebo-controlled, multicenter phase III trial with 1,342 patients

Critical Care Medicine ◽

10.1097/00003246-200103000-00006 ◽

2001 ◽

Vol 29 (3) ◽

pp. 503-510 ◽

Cited By ~ 205

Author(s):

Edward Abraham ◽

Pierre-François Laterre ◽

Jorge Garbino ◽

Susan Pingleton ◽

Thomas Butler ◽

...

Keyword(s):

Septic Shock ◽

Severe Sepsis ◽

Tumor Necrosis ◽

Tumor Necrosis Factor Receptor ◽

Phase Iii ◽

Double Blind ◽

Phase Iii Trial ◽

Double Blind Placebo ◽

Multicenter Phase ◽

Necrosis Factor

6566 POSTER Updated Safety and Efficacy Results From RADIANT-2 – a Randomized, Double-blind, Multicenter, Phase III Trial of Everolimus + Octreotide LAR Vs Placebo + Octreotide LAR in Pts With Advanced Neuroendocrine Tumours (NET)

European Journal of Cancer ◽

10.1016/s0959-8049(11)71877-9 ◽

2011 ◽

Vol 47 ◽

pp. S461

Author(s):

S. Ricci ◽

P. Ruszniewski ◽

P. Tomasetti ◽

V. Jehl ◽

S. Saletan ◽

...

Keyword(s):

Neuroendocrine Tumours ◽

Phase Iii ◽

Double Blind ◽

Phase Iii Trial ◽

Safety And Efficacy ◽

Octreotide Lar ◽

6561 POSTER Updated Survival and Safety Data From RADIANT-3 – a Randomized, Double-blind, Placebo-controlled, Multicenter, Phase III Trial of Everolimus in Patients With Advanced Pancreatic Neuroendocrine Tumours (pNET)

European Journal of Cancer ◽

10.1016/s0959-8049(11)71872-x ◽

2011 ◽

Vol 47 ◽

pp. S459 ◽

Cited By ~ 2

Author(s):

C. Lombard-Bohas ◽

E. Van Cutsem ◽

J. Capdevila ◽

E.G.E. de Vries ◽

P. Tomassetti ◽

...

Keyword(s):

Neuroendocrine Tumours ◽

Safety Data ◽

Phase Iii ◽

Double Blind ◽

Phase Iii Trial ◽

Double Blind Placebo ◽

Multicenter Phase ◽

Pancreatic Neuroendocrine Tumours

Custodiol-N versus custodiol: A prospective randomized double blind multicenter phase III trial

The Thoracic and Cardiovascular Surgeon ◽

10.1055/s-0034-1367380 ◽

2014 ◽

Vol 62 (S 01) ◽

Author(s):

G. Szabó ◽

A. Weymann ◽

B. Schmack ◽

D. Badowsky-Zyla ◽

G. Veres ◽

...

Keyword(s):

Phase Iii ◽

Double Blind ◽

Phase Iii Trial ◽

Faculty Opinions recommendation of Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1146988.604098 ◽

2009 ◽

Author(s):

Frank Pessler

Keyword(s):

Juvenile Idiopathic Arthritis ◽

Phase Iii ◽

Efficacy And Safety ◽

Double Blind ◽

Phase Iii Trial ◽

Double Blind Placebo ◽

Withdrawal Phase ◽

Systemic Onset